177 related articles for article (PubMed ID: 21297650)
1. Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
Filippi M
Nat Rev Neurol; 2011 Feb; 7(2):74-5. PubMed ID: 21297650
[No Abstract] [Full Text] [Related]
2. Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
Hohlfeld R
Nat Rev Neurol; 2011 Jul; 7(8):425-7. PubMed ID: 21750524
[No Abstract] [Full Text] [Related]
3. New drugs may improve, complicate treatment for multiple sclerosis.
Link H; Martin R
Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513
[No Abstract] [Full Text] [Related]
4. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Hecht B
Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
[TBL] [Abstract][Full Text] [Related]
5. ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
Hopkins CR
ACS Chem Neurosci; 2011 Mar; 2(3):116-7. PubMed ID: 22778861
[No Abstract] [Full Text] [Related]
6. Trial watch: Phase III promise for oral multiple sclerosis therapy.
Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
[No Abstract] [Full Text] [Related]
7. [Emerging treatments for multiple sclerosis].
Nau JY
Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
[No Abstract] [Full Text] [Related]
8. Update on emerging therapies for multiple sclerosis.
Yiu EM; Banwell B
Expert Rev Neurother; 2010 Aug; 10(8):1259-62. PubMed ID: 20662750
[TBL] [Abstract][Full Text] [Related]
9. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
[No Abstract] [Full Text] [Related]
10. Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.
Goldman MD; Naismith RT
Neurology; 2015 Mar; 84(9):864-5. PubMed ID: 25636716
[No Abstract] [Full Text] [Related]
11. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
Popova NF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
[No Abstract] [Full Text] [Related]
12. FTY720 and central memory: out of sight, out of mind.
Slavin AJ; Zamvil SS
Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
[No Abstract] [Full Text] [Related]
13. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
Haghikia A; Gold R
Am J Pathol; 2010 Jun; 176(6):2599-601. PubMed ID: 20395429
[TBL] [Abstract][Full Text] [Related]
14. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
Mehling M; Kappos L; Derfuss T
Curr Neurol Neurosci Rep; 2011 Oct; 11(5):492-7. PubMed ID: 21789537
[TBL] [Abstract][Full Text] [Related]
16. Tumefactive multiple sclerosis lesions under fingolimod treatment.
Visser F; Wattjes MP; Pouwels PJ; Linssen WH; van Oosten BW
Neurology; 2012 Nov; 79(19):2000-3. PubMed ID: 23035065
[No Abstract] [Full Text] [Related]
17. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
Klatt J; Hartung HP; Hohlfeld R
Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161
[TBL] [Abstract][Full Text] [Related]
18. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S
Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
[No Abstract] [Full Text] [Related]
19. Multiple sclerosis: closing in on an oral treatment.
Martin R
Nature; 2010 Mar; 464(7287):360-2. PubMed ID: 20237554
[No Abstract] [Full Text] [Related]
20. Fingolimod and multiple sclerosis: four cautionary tales.
Bourdette D; Gilden D
Neurology; 2012 Nov; 79(19):1942-3. PubMed ID: 23035058
[No Abstract] [Full Text] [Related]
[Next] [New Search]
